Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.
Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.
Vertex Pharmaceuticals is the worldwide leader in cystic fibrosis treatment -- and its drugs have generated blockbuster revenue. The company has expanded into other therapeutic areas in recent years ...
Shares of Vertex Pharmaceuticals Inc. VRTX slid 1.14% to $437.01 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.09% to ...
The Dow is up triple digits, but the S&P 500 and Nasdaq are trading modestly higher Stocks are scattered today, as Wall Street tries to overcome a dismal jobs report and choppy tech sector sentiment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback